Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease
Tamique Mason, Otávio R. Coelho‐Filho, Subodh Verma, Biswajit Chowdhury, Fei Zuo, Adrian Quan, Kevin E. Thorpe, Christopher Bonneau, Hwee Teoh, Richard E. Gilbert, Lawrence A. Leiter, Peter Jüni, Bernard Zinman, Michael Jerosch‐Herold, C. David Mazer, Andrew T. Yan, Kim A. Connelly
Topics & Concepts
EmpagliflozinMedicineCardiologyInternal medicineCoronary artery diseasePlaceboType 2 diabetesDiabetes mellitusType 2 Diabetes MellitusEndocrinologyPathologyAlternative medicineCardiovascular Function and Risk FactorsDiabetes Treatment and ManagementParathyroid Disorders and Treatments